Reductions in LVOT gradients, NYHA class and NT-proBNP with cardiac myosin inhibitor in HCM - PACE-CME

Reductions in LVOT gradients NYHA class and NTproBNP with cardiac myosin inhibitor in HCM

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

A positive view on a negative trial with DOAC after TAVR
A positive view on a negative trial with DOAC after TAVR
ACC.22
A positive view on a negative trial with DOAC after TAVR
- Megan Coylewright, MD
EHR-based intervention improves quality care for patients with HF
EHR-based intervention improves quality care for patients with HF
ACC.22
EHR-based intervention improves quality care for patients with HF
- Tariq Ahmad, MD
Beginning of an era: Treatment of elevated Lp(a)
Beginning of an era: Treatment of elevated Lp(a)
ACC.22
Beginning of an era: Treatment of elevated Lp(a)
- Steven Nissen, MD
Study with ASO targeting ANGPTL3 mRNA highlights importance of rigorous evaluation of new therapies
Study with ASO targeting ANGPTL3 mRNA highlights importance of rigorous evaluation of new therapies
ACC.22
Study with ASO targeting ANGPTL3 mRNA highlights importance of rigorous evaluation of new therapies
- Brian Bergmark, MD